Mastocytosis: Clinical Trials

14 trials for Mastocytosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 14 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 10, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 26Completed 4, Terminated 1, Withdrawn 1

Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
BLU-263, Azacitidine - Advanced Systemic Mastocytosis
Phase 1TerminatedBlueprint Medicines Corporation92023-09-252025-04-10
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes
Phase 1Active not recruitingMacroGenics1302022-07-132026-07-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Phase 1CompletedCity of Hope Medical Center132020-11-182026-01-28
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Phase 1 / Phase 2TerminatedGT Biopharma, Inc.122020-01-012022-11-10
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
AK002 - Indolent Systemic Mastocytosis
Phase 1CompletedAllakos Inc.252016-06-012019-03-13
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Avapritinib - Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
Phase 1CompletedBlueprint Medicines Corporation862016-03-102023-03-17
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
DCC-2618 - Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
Phase 1CompletedDeciphera Pharmaceuticals, LLC2822015-11-012023-12-13
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
Phase 1CompletedNational Cancer Institute (NCI)452011-01-012014-04-29
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Phase 1CompletedNational Cancer Institute (NCI)422009-08-012014-03-17
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Phase 1 / Phase 2CompletedAsan Medical Center472009-01-012013-02-20
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Nilotinib - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals5072005-04-012021-06-29
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
PS-341, Doxil, Velcade - Breast Cancer, Leukemia
Phase 1 / Phase 2CompletedUNC Lineberger Comprehensive Cancer Center1072001-05-012012-05-18
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center212000-05-012020-01-21
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole - Chronic Myeloproliferative Disorders, Infection
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2013-02-15

Narrower conditions

Leukemia, Mast-Cell (10)  ·  Leukemia, Hairy Cell (8)  ·  Leukemia, Myeloid, Acute (8)  ·  Mastocytosis, Systemic (8)  ·  Burkitt Lymphoma (7)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (7)  ·  Hodgkin Disease (6)  ·  Intraocular Lymphoma (6)  ·  Leukemia, Large Granular Lymphocytic (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Leukemia, Myelomonocytic, Chronic (6)  ·  Lymphoma, B-Cell, Marginal Zone (6)  ·  Lymphoma, Extranodal NK-T-Cell (6)  ·  Lymphoma, Follicular (6)  ·  Lymphoma, Large B-Cell, Diffuse (6)

Broader conditions

Immune System Diseases (14)  ·  Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Hematologic Diseases (13)  ·  Hemic and Lymphatic Diseases (13)  ·  Leukemia, Myeloid (13)  ·  Mast Cell Activation Disorders (13)  ·  Bone Marrow Diseases (11)  ·  Disease Attributes (10)  ·  Leukemia (10)  ·  Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Chronic Disease (9)  ·  Immunoproliferative Disorders (9)

Interventions

AK002 (1)  ·  Acetaminophen (1)  ·  Azacitidine (1)  ·  Bortezomib (1)  ·  Calcium Dobesilate (1)  ·  Cyclosporine (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Edetic Acid (1)  ·  Ethanol (1)  ·  Ibuprofen (1)  ·  MK 2206 (1)  ·  Mycophenolic Acid (1)  ·  Pentetic Acid (1)  ·  Peripheral Blood Stem Cell Transplantation (1)

Sponsors

Blueprint Medicines Corporation (2)  ·  National Cancer Institute (NCI) (2)  ·  Allakos Inc. (1)  ·  Asan Medical Center (1)  ·  City of Hope Medical Center (1)  ·  Deciphera Pharmaceuticals, LLC (1)  ·  Fred Hutchinson Cancer Center (1)  ·  GT Biopharma, Inc. (1)  ·  M.D. Anderson Cancer Center (1)  ·  MacroGenics (1)  ·  Novartis Pharmaceuticals (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)

Countries

United States (11)  ·  Germany (4)  ·  Canada (3)  ·  Italy (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  France (2)  ·  Norway (2)  ·  South Korea (2)  ·  Spain (2)  ·  Australia (1)  ·  Austria (1)  ·  Denmark (1)  ·  Finland (1)

Top investigators

David Maloney (1)  ·  Elizabeth C. Dees, MD (1)  ·  Frank Perabo, MD, PhD (1)  ·  Ibrahim T Aldoss (1)  ·  John Deeken (1)  ·  Jorge Cortes, MD (1)  ·  Kyoo H. Lee, MD (1)  ·  Marcus Maurer, MD (1)  ·  Mark B Juckett, MD (1)  ·  Maryam Fouladi (1)  ·  Patrick Chaftari, MD (1)  ·  Robert Z. Orlowski, MD, PhD (1)

Results publications

PMID 16775235, PMID 17715389, PMID 18327587, PMID 21098399, PMID 22259028, PMID 23547655, PMID 24057647, PMID 24474568, PMID 26002753, PMID 32499241, PMID 32804590, PMID 34873347, PMID 35622074, PMID 35640224, PMID 35790816

NIH funding

2015 (1), P01CA078902 (1), P30CA015704 (1), P30CA033572 (1), U01CA097452 (1), U01CA121947 (1)